Cryoport, Inc.
About Cryoport, Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $176.2M
- Net income
- $78.3M
- Total assets
- $765.0M
- Market cap
- $791.3M
- Gross margin
- 47.1%
- Operating margin
- -20.9%
- Net margin
- 44.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $176.2M
- Cost of revenue
- $93.1M
- Gross profit
- $83.1M
- Operating expenses
- $119.9M
- Operating income
- -$36.8M
- Income tax
- $1.8M
- Net income
- $78.3M
- EPS (basic)
- $1.40
- EPS (diluted)
- $1.40
Balance sheet
- Total assets
- $765.0M
- Current assets
- $476.2M
- Total liabilities
- $262.4M
- Current liabilities
- $219.0M
- Shareholders’ equity
- $502.6M
Cash flow
- Operating cash flow
- -$8.6M
- Investing cash flow
- $250.3M
- Financing cash flow
- -$21.1M
- Net cash flow
- $205.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $791.3M
- P/E ratio
- 11.1
- EPS (diluted)
- $1.4
- Shares outstanding
- 51.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $78.3M in FY2025.
- Revenue declined 21% from FY2021 to FY2025.
- Gross margin of 47.1%, net margin 44.4%.
- Trading 6% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 11.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cryoport, Inc..
Write a review
News about Cryoport, Inc.
News & sentiment via Polygon.io
